Antibodies recognizing plasminogen, a key component of the fibrinolytic system, associate with venous thrombotic events in PR3-ANCA vasculitis. Here, we investigated the prevalence and function of anti-plasminogen antibodies in independent UK and Dutch cohorts of patients with ANCA-associated vasculitis (AAV).
Recently, it was reported that a subset of patients with PR3-ANCA harbor antibodies against human plasminogen.
3 These anti-plasminogen antibodies recognize a structure within the protease domain and their presence correlated with venous thromboembolic events (VtEs), suggesting functional interference with coagulation and/ or fibrinolysis. 3 The relationship between anti-plasminogen antibodies and coagulation may also be directly relevant to glomerular injury and the evolution of fibrinoid necrosis, a hallmark lesion of AAV. In AAV, vascular injury is mediated by ANCAinduced neutrophil and monocyte activation 4 and characterized by the influx of inflammatory cells with fibrinoid necrosis affecting glomeruli and occasionally small arteries. It is possible that fibrinoid necrosis is in fact an aberrant repair mechanism that follows vascular injury. This hypothesis would account for histologic and compositional similarities between fibrinoid necrosis and conventional fibrin clots 5;6 and explain the importance of the fibrinolytic system in renal injury, as shown by animal models of rapidly progressive glomerulonephritis. 7;8 Under these circumstances, down-regulation of fibrinolysis by anti-plasminogen antibodies in AAV patients would promote persistent or extensive fibrinoid necrosis.
In this study, we investigated the presence and functionality of anti-plasminogen antibodies in independent cohorts of United Kingdom (UK) and Dutch patients with AAV. We show that immunoglobulin from AAV patients retards fibrinolysis and that seropositivity for these antibodies correlates with reduced renal function and the presence of hallmark histopathologic renal lesions. We also detected antibodies against the partially homologous serine protease tissue plasminogen activator (tPA) in some patients.
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METHODS
Study population
UK cohort
Stored frozen plasma exchange (PEX) fluid from 74 consenting AAV patients treated at
University Hospital Birmingham was studied. All patients satisfied Chapel Hill
Conference consensus criteria 37 and received PEX for severe renal disease (serum creatinine ≥ 500 μmol/L or dialysis dependency) and/or pulmonary hemorrhage.
Pulsed intravenous steroids were not routinely used, and the majority of patients started plasma exchange concurrently with oral corticosteroids. Cyclophosphamide (daily oral or pulsed intravenous) was initiated at the same time or immediately after corticosteroids and plasma exchange. Plasma exchange effluent was collected at the time of the first exchange.
ANCA positivity and specificity of paired serum from these patients were determined
at the time of diagnosis by indirect immunofluorescence and ELISA respectively, at the Clinical Immunology Laboratory, University of Birmingham, Birmingham, UK.
Twelve ANCA-negative patients with other renal diseases (anti-glomerular basement membrane [GBM] disease, n = 7; systemic lupus erythematosus, n = 3; myeloma, n = 1; antibody-mediated renal allograft rejection, n = 1) who had also undergone PEX were used as a disease control cohort. Laboratory personnel (n = 50) served as a healthy control cohort, and serum was separated from peripheral blood collected after the study started.
IgG was purified from patient PEX fluid and healthy control serum by protein G affinity chromatography (GE Healthcare, Buckinghamshire, UK) and eluted with 0.1 M glycine (pH 2.7). 38 Concentrations were determined by spectrophotometry. IgG samples were purified at the time of conducting this study, and results of the original ANCA testing were verified by retesting derived IgG samples in the Clinical Laboratory. AAV-IgG were also screened by ELISA for anti-cardiolipin antibodies using a kit available from the Binding Site (Birmingham, UK).
For separate assays using serial samples collected over time, serum from two AAV patients was available. For these experiments, sera from 127 healthy blood donors were used as the control population.
Dutch cohort
A total of 38 patients with AAV of whom serum or PEX fluid was available were recruited. the majority of patients (33/38) were seen in one nephrology unit (Meander Medical Center, Amersfoort, the Netherlands). All patients met the Chapel Hill criteria for diagnosis of AAV. 37 The ANCA specificity of each patient was determined at Leiden University Medical Center using an ELISA kit from Wieslab (Lund, Sweden). IgG was isolated from patient sera/PEX using the Melon Gel IgG Purification Kit (Pierce Protein Research Products, thermo Scientific). the integrity of isolated IgG was confirmed through SDS-PAGE and visualization through Coomassie blue staining.
Glomerular filtration rates were estimated (eGFR) at the time of serum/PEX (baseline)
and at 1 year, using the four-variable Modification of Diet in Renal Disease equation (MDRD). 10;11 To evaluate an independent predictive effect of anti-plasminogen antibodies on eGFR at 1 year follow-up, we corrected for the eGFR at baseline. the corrected eGFR at 1 year was defined as the difference between the observed eGFR at 1 year and its linear prediction on the basis of baseline eGFR.
39;40
Nineteen patients had a serum sample taken or underwent plasma exchange (PEX) at the same day a renal biopsy was performed. Two independent observers, who were unaware of the clinical data, reviewed all biopsies for glomerular lesions according to a previously designed scoring protocol. 41 For each biopsy silver, Periodic acid- used. In assays requiring the use of sera, a 1:100 dilution was used.
For competition assays, dose-response studies were performed to select the lowest concentration of IgG reactive on each antigen (1.25 μg/ml). IgG was preincubated (2 hours at 25°C) with increasing concentrations (0-1 μM) of native soluble plasminogen or plasminogen denatured by heating with 5% β-mercaptoethanol (5 minutes at 100°C). Before use, denatured plasminogen was diluted to the required concentration and residual levels of β-mercaptoethanol were calculated at 0.05%. the integrity of
IgG after preincubation with denatured plasminogen was confirmed by SDS-PAGE and visualization through Coomassie blue staining. The subsequent ELISA was performed as described above. For separate assays, plasminogen denatured in this way was also used as the coat antigen.
For alternative competition assays, IgG was preincubated with tPA or plasmin that had been inactivated through mixing with Nα-tosyl-L-lysine chloromethyl ketone-HCl (tLCK, Sigma) according to a protocol previously described. Briefly, 12 μM plasmin was incubated with 6 mM tLCK in phosphate buffered saline (pH 7.4) for 100 minutes at 25°C. 14 Using this method, the proteolytic activity of plasmin is reportedly inhibited in excess of 99%. 14 The inactivation of plasmin was confirmed by SDS-PAGE and Coomassie blue staining after mixing inactivated plasmin with IgG under the conditions required for the ELISA. 
Immunoprecipitation Western
Fibrinolysis assays UK AAV-IgG samples
The functional effects of anti-plasminogen antibodies were determined in vitro using a slight modification of a method previously described. 14 
Statistical analysis
A strict analysis criterion was used to determine whether patient samples reacted with plasminogen or other given antigens and also whether IgG was able to interfere with fibrinolysis. Any values exceeding the mean + 2 SD of the healthy control population were considered positive. these criteria had to be met on > 50% of the occasions tested. Differences between groups were analyzed using one-way ANOVA followed by Bonferroni or Dunnett's post hoc tests.
A Mann-Whitney U test (two-tailed) was performed to assess differences in renal function and the percentage of glomerular lesions according to anti-plasminogen antibody subgroup. P ≤ 0.05 was considered significant.
All statistical tests were performed using Graphpad Prism (version 4; Graphpad, San Diego, CA) and the SPSS statistical software package for Windows (version 16.0; SPSS, Chicago, IL).
RESULTS
Identification of anti-plasminogen antibodies in AAV-IgG
Anti (**p < 0.01; Table 1 ). In contrast, soluble plasminogen was less efficient in reducing dual positive IgG binding to tPA (47.23 ± 0.58%; **p < 0.01). Collectively, these data suggest that AAV-IgG from the patients tested in these experiments bound to the fibrinolysis-associated serine proteases with the differing relative affinities:
tPA > plasminogen > plasmin. 
Anti-plasminogen antibodies in AAV-IgG compromise fibrinolysis
UK AAV-IgG also retarded in vitro fibrinolysis compared with HC-IgG (Figure 4 A).
IgG were classified as significantly retarding fibrinolysis if they extended time to 50%
fibrinolysis by more than the mean + 2 SD effect of the HC-IgG cohort. Accordingly, 
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Transient nature of anti-plasminogen antibodies
The UK AAV-IgG were all obtained during acute disease. Longitudinal testing of these patients was not possible but, intriguingly, serial samples from two other AAV patients suggested that anti-plasminogen antibodies may disappear with treatment ( Figure   5 ). However, in the Dutch cohort, one patient tested positive for anti-plasminogen antibodies while being in clinical remission. these observations merit further examination.
A B Figure 5 . Transient nature of anti-plasminogen and anti-tissue plasminogen activator antibodies. Serial serum samples (diluted 1:100) from two patients collected over 52 weeks were screened for antibodies against plasminogen (A) and tissue plasminogen activator (B). Antibody titers were correlated with disease activity using the Birmingham Vasculitis Activity Scoring (BVAS) system. Data are means ± SEM (n = 3). the dotted line is the positive cut-off representing the mean + 2 standard deviations of the healthy controls. *p < 0.05 compared to the antibody titer at presentation.
Seropositivity for anti-plasminogen antibodies correlates to reduced renal function
Serum creatinine measurements made at the same time as serum samples were collected for this study were available for 36/38 Dutch patients. the 10 patients who tested positive for anti-plasminogen antibodies had a significantly higher serum creatinine and a lower estimated GFR (eGFR; four-variable MDRD equation 10;11 ) compared with patients who tested negative for anti-plasminogen antibodies ( Table 2) .
At 12-month follow-up, patients with anti-plasminogen antibodies in their initial serum samples still had a higher serum creatinine, and a lower eGFR, compared with patients who tested negative for anti-plasminogen antibodies, whereas there was no difference in corrected eGFR at 12 months, suggesting that the effect of differences in baseline eGFR persisted. Seven of 19 biopsied patients were positive for anti-plasminogen antibodies: renal biopsies from these 7 patients showed higher percentages of glomeruli with fibrinoid necrosis (p < 0.05) and cellular crescents (p < 0.001; Table 3 ). No difference in globally sclerosed glomeruli or fibrous crescents was found.
These results demonstrate that patients with anti-plasminogen antibodies show more active renal lesions than patients without anti-plasminogen antibodies. No Anti-PLG Antibodies (n = 12)
p-value
Glomeruli with fibrinoid necrosis percent of total glomeruli ± SD 21 ± 18 5 ± 7 < 0.05
Glomeruli with crescents percent of total glomeruli ± SD 52 ± 21 20 ± 17 < 0.01
Glomeruli with cellular crescents percent of total glomeruli ± SD 37 ± 23 9 ± 7 < 0.001
Glomeruli with fibrous crescents percent of total glomeruli ± SD 15 ± 15 11 ± 17 NS Glomeruli with global sclerosis percent of total glomeruli ± SD 13 13 ± 11 NS the percentage of glomeruli (mean ± SD) showing hallmark renal lesions of ANCA-associated glomerulonephritis is reported in biopsies of anti-plasminogen antibody (anti-PLG)-negative patients compared with anti-plasminogen antibody-positive patients. NS, not significant.
DISCUSSION
We identified anti-plasminogen antibodies in approximately 25% of patients in two independent AAV cohorts. Furthermore, anti-tPA antibodies were detected in 17.6%
of AAV patients from one cohort, and the majority of AAV-IgG that inhibited in vitro fibrinolysis harbored either anti-plasminogen and/or anti-tPA antibodies. Importantly, there was also a correlation between anti-plasminogen antibodies and the proportion of glomeruli exhibiting fibrinoid necrosis and cellular crescents.
Antibodies that react with plasminogen/plasmin and other serine proteases of the coagulation/fibrinolysis cascade were previously detected in patients with autoimmune disease, particularly as a subspecies of aCL antibodies. 9;12-14 Notably, high affinity monoclonal anti-plasmin antibodies isolated from patients with antiphospholipid syndrome (APS) bind plasminogen, thrombin, factor X and activated protein C with considerably lower affinity. 12;14 Typically, these autoantibodies appear to cross-react with epitopes within the catalytic domains of serine proteases and conformational epitopes in β2 glycoprotein 1.
In contrast, IgG derived from AAV patients preferentially bind plasminogen with infrequent binding to plasmin. Cross-inhibition studies also suggest lower affinity binding to plasmin than plasminogen in dual positive samples, and aCL antibodies did not account for anti-plasminogen antibodies in AAV patients. We examined total IgG rather than affinity-purified IgG, but collectively, the data suggest that anti-plasminogen antibodies in AAV are likely to be distinct from related antibodies in other autoimmune diseases. Anti-plasminogen antibodies isolated from PR3-ANCA vasculitis patients in a North
American cohort seem to recognize an epitope within the protease domain, but again these antibodies did not bind to plasmin nor thrombin for reasons that are unclear. 3 The detection of anti-tPA antibodies in AAV is intriguing. Tissue plasminogen activator is a serine protease that exhibits an overall 35% shared identity with plasminogen.
In addition to homologous protease domains, tPA and plasminogen contain kringle domains. Anti-tPA antibodies characterized in two APS patients bound to its protease domain but did not cross-react with plasminogen or thrombin. 15 AAV-IgG which display dual reactivity against plasminogen and tPA may comprise distinct immunoglobulins which bind exclusively to one or other serine protease or alternatively, crossreactive immunoglobulins recognizing common epitopes. The cross-inhibition studies favor the existence of cross-reactive immunoglobulins in at least some AAV patients.
The previously proposed core epitope for anti-plasminogen antibodies isolated from PR3-ANCA patients is a 'PHxQ' motif, whereas alignment of plasminogen and tPA reveals that of these 3 residues, only glutamic acid (Q) is conserved. This study showed the capacity of anti-plasminogen and anti-tPA antibodies to delay fibrinolysis, which supports the hypothesis that they have pathogenic significance.
Studies in four distinct AAV patient cohorts have identified an increased incidence of VTEs, which does not seem to be attributable to conventional prothrombotic risk factors. 16;17 Meanwhile, anti-plasminogen antibodies correlated with VTEs in PR3-ANCA patients. 3 Although one of the Dutch patients with particularly high titers of anti-plasminogen antibodies had a history of deep venous thrombosis, we do not have comprehensive data on VTEs in the cohorts. Nevertheless, we hypothesized that anti-plasminogen antibodies might also influence glomerular pathology through a disturbance of fibrinolysis in the microvasculature.
In AAV, vascular injury is mediated by ANCA-induced neutrophil and monocyte activation and characterized histopathologically by an influx of inflammatory cells with fibrinoid necrosis in small vessel walls. 18 In the renal biopsy, fibrinoid necrosis is apparent in glomeruli. Although fibrinoid necrosis is a ubiquitous feature of ANCAassociated vascular injury, 19 little is known about its pathogenesis. 20 Meanwhile, there are striking parallels in composition between fibrinoid necrosis and the fibrin clot in vascular repair. Both lesions consist primarily of fibrin, platelets, leucocytes and extracellular matrix molecules such as fibronectin. 5;6;21-23 Conceivably, fibrinoid necrosis may therefore originate from a flaw in the physiological vascular repair mechanism wherein the fibrin clot fails to be removed after its scaffold function for angiogenesis is completed. This disturbance may be initiated or accelerated by anti-plasminogen antibodies.
To this end, we scored histopathologic lesions in patients with biopsy-proven ANCAassociated glomerulonephritis, and found that the occurrence of anti-plasminogen antibodies was associated with higher percentages of glomeruli with fibrinoid necrosis and cellular crescents, accompanied by more severely reduced renal function.
Fibrinoid necrosis is often encountered in glomeruli with cellular crescents, and there are indications that fibrin is an important mediator of extracapillary proliferation. Fibrinogen leakage through damaged glomerular basement membranes could potentially trigger the formation of crescents. Several experimental models support a role of coagulation, and fibrin in particular, in the formation of fibrinoid necrosis and crescents. [24] [25] [26] Experimental anti-GBM glomerulonephritis has a more severe course in tPA and plasminogen knockout mice, with more fibrin deposition, tuft necrosis and crescents, in addition to more severe renal failure. 8 Other knockout models demonstrate that fibrinogen deficiency is protective in experimental crescentic glomerulonephritis. 7 the role of glomerular fibrin deposition in crescent formation is underlined by experimental data that showed that defibrinating agents substantially prevented crescent formation and renal failure. [27] [28] [29] In AAV, large studies on the efficacy of anti-coagulant therapies have not been performed, but case reports suggest that heparin and defibrotide can be therapeutically beneficial. [30] [31] [32] [33] [34] Similarly, systemic plasminogen concentrates or recombinant tPA could be of interest. Recombinant tPA treatment reduced fibrin deposition and crescent formation and improved renal function in experimental crescentic glomerulonephritis, 35 whereas streptokinase reduced glomerular fibrin deposition and preserved renal function when used early after disease onset.
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In conclusion, approximately 25% of AAV patients harbor anti-plasminogen antibodies. Anti-plasminogen antibodies, particularly in combination with anti-tPA antibodies, delay fibrinolysis in vitro and are related to hallmark renal histologic lesions that are closely associated with disturbances in coagulation. Therapies aiming at enhancing or replacing fibrinolytic activity may be of benefit in AAV patients with anti-plasminogen and anti-tPA antibodies.
